Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ACRV
stocks logo

ACRV

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.466
-13.76%
--
--
-0.495
-2.94%
--
--
-0.517
-6.06%
Estimates Revision
The market is revising No Change the revenue expectations for Acrivon Therapeutics, Inc. (ACRV) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 81.20%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+81.20%
In Past 3 Month
Wall Street analysts forecast ACRV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACRV is 10.60 USD with a low forecast of 6.00 USD and a high forecast of 19.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast ACRV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACRV is 10.60 USD with a low forecast of 6.00 USD and a high forecast of 19.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.410
sliders
Low
6.00
Averages
10.60
High
19.00
Current: 2.410
sliders
Low
6.00
Averages
10.60
High
19.00
Oppenheimer
Oppenheimer
Outperform
downgrade
$9 -> $8
2025-08-14
Reason
Oppenheimer
Oppenheimer
Price Target
$9 -> $8
2025-08-14
downgrade
Outperform
Reason
Oppenheimer lowered the firm's price target on Acrivon Therapeutics to $8 from $9 and keeps an Outperform rating on the shares following Q2 results. The firm notes Phase 1 trial of ACR-2316 is on track for the second half of 2025.
JonesResearch
Buy
to
Hold
downgrade
2025-05-16
Reason
JonesResearch
Price Target
2025-05-16
downgrade
Buy
to
Hold
Reason
Oppenheimer
Oppenheimer
Outperform
downgrade
$10 -> $9
2025-05-14
Reason
Oppenheimer
Oppenheimer
Price Target
$10 -> $9
2025-05-14
downgrade
Outperform
Reason
Oppenheimer lowered the firm's price target on Acrivon Therapeutics to $9 from $10 and keeps an Outperform rating on the shares. The firm is adjusting its model after the company's Q1 results and updates on its cash and share position, the analyst tells investors in a research note.
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Reiterates
$19
2025-03-28
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$19
2025-03-28
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Maintains
$22 → $19
2025-03-26
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$22 → $19
2025-03-26
Maintains
Strong Buy
Reason
Citizens Capital Markets
Silvan Tuerkcan
Buy
Reiterates
$17
2025-03-26
Reason
Citizens Capital Markets
Silvan Tuerkcan
Price Target
$17
2025-03-26
Reiterates
Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Acrivon Therapeutics Inc (ACRV.O) is -1.21, compared to its 5-year average forward P/E of -2.70. For a more detailed relative valuation and DCF analysis to assess Acrivon Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.70
Current PE
-1.21
Overvalued PE
-1.00
Undervalued PE
-4.40

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
90.78
Current PS
0.00
Overvalued PS
272.54
Undervalued PS
-90.98
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

ACRV News & Events

Events Timeline

(ET)
2025-11-13
16:47:03
Acrivon Therapeutics announces Q3 earnings per share of 47 cents, below consensus estimate of 58 cents.
select
2025-08-13 (ET)
2025-08-13
16:44:26
Acrivon Therapeutics reports Q2 EPS (55c), consensus (58c)
select
2025-05-14 (ET)
2025-05-14
16:31:10
Acrivon Therapeutics reports Q1 EPS (51c), consensus (65c)
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
6.0
11-25Benzinga
HC Wainwright & Co. Affirms Buy Rating for Acrivon Therapeutics, Keeps $19 Price Target Intact

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.

  • Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters, enhancing their trading strategies.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and experiences.

  • Market Winning Tools: The platform is designed to provide traders with the tools and information necessary to succeed in their trading endeavors.

[object Object]
Preview
4.0
11-14TipRanks
Top Analysts Recommend 3 Best Stocks to Purchase Now, 11/14/2025

  • Top Stock Picks: Analysts have identified three stocks as Strong Buys, each receiving new Buy ratings and showing significant upside potential.

  • Exodus Movement (EXOD): This crypto technology company has a Buy rating from all five Top Analysts, with a 12-month price target suggesting a 159.89% upside, despite a recent price target decrease.

  • DoorDash (DASH): The food delivery platform has 20 out of 26 Top Analysts rating it as a Buy, with a 12-month price target indicating a 48.05% upside, although the rating was recently upgraded to Hold.

  • Acrivon Therapeutics (ACRV): This biotech firm has received Buy ratings from all three Top Analysts, with a remarkable 672.95% upside projected in its 12-month price target.

[object Object]
Preview
6.5
11-01TipRanks
Experts Forecast Potential 550% Surge for These 2 'Strong Buy' Penny Stocks

  • Market Overview: The S&P 500 has risen 16% year-to-date, driven by Big Tech's advancements in AI and digital infrastructure, while opportunities also exist in the penny-stock sector for potential high returns.

  • Acrivon Therapeutics: Acrivon is a clinical-stage biotech focused on precision oncology, with promising drug candidates ACR-368 and ACR-2316 showing potential for significant market upside, supported by positive analyst ratings and upcoming clinical data.

  • VistaGen: VistaGen is developing innovative treatments for central nervous system disorders, particularly social anxiety disorder, with its lead candidate fasedienol nearing key trial milestones, and analysts expressing confidence in its potential success.

  • Analyst Insights: Both Acrivon and VistaGen have received strong buy ratings from analysts, highlighting their promising pipelines and potential for substantial stock price increases, with Acrivon projected to rise by 553% and VistaGen by 205% over the next year.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Acrivon Therapeutics Inc (ACRV) stock price today?

The current price of ACRV is 2.41 USD — it has increased 5.7 % in the last trading day.

arrow icon

What is Acrivon Therapeutics Inc (ACRV)'s business?

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision oncology medicines. It uses its precision Generative Phosphoproteomics platform, Acrivon Predictive Precision Proteomics (AP3), to develop its pipeline of oncology drug candidates. Its lead candidate, ACR-368, is a selective small molecule inhibitor which targets CHK1 and CHK2 at sub single-digit nM and single-digit nM potency in intact cells, respectively, in a registrational Phase II trial across multiple solid tumor types. Using its AP3 platform, it has developed a predictive OncoSignature test for ACR-368, called ACR-368 OncoSignature, that can predict patient response to ACR-368 monotherapy and therefore improve the clinical overall response rate (ORR) and has the potential to enable drug development. Its preclinical program, ACR-2316, is advancing in investigational new drug-enabling studies. It is a novel, dual WEE1 and PKMYT1 inhibitor small molecule development candidate.

arrow icon

What is the price predicton of ACRV Stock?

Wall Street analysts forecast ACRV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACRV is 10.60 USD with a low forecast of 6.00 USD and a high forecast of 19.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Acrivon Therapeutics Inc (ACRV)'s revenue for the last quarter?

Acrivon Therapeutics Inc revenue for the last quarter amounts to -19.69M USD, decreased -21.69 % YoY.

arrow icon

What is Acrivon Therapeutics Inc (ACRV)'s earnings per share (EPS) for the last quarter?

Acrivon Therapeutics Inc. EPS for the last quarter amounts to -13182000.00 USD, decreased -28.01 % YoY.

arrow icon

What changes have occurred in the market's expectations for Acrivon Therapeutics Inc (ACRV)'s fundamentals?

The market is revising No Change the revenue expectations for Acrivon Therapeutics, Inc. (ACRV) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 81.20%.
arrow icon

How many employees does Acrivon Therapeutics Inc (ACRV). have?

Acrivon Therapeutics Inc (ACRV) has 75 emplpoyees as of December 05 2025.

arrow icon

What is Acrivon Therapeutics Inc (ACRV) market cap?

Today ACRV has the market capitalization of 76.05M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free